Your session is about to expire
← Back to Search
rTMS for Depression
Phase 1
Waitlist Available
Led By Jong H Yoon, MD
Research Sponsored by Davidzon, Guido, M.D.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up assessed during pet scans before and after rtms therapy (90 minutes per scan)
Awards & highlights
Summary
This trial will use a radioactive marker to study if transcranial magnetic stimulation can help with changes in the brain linked to depression.
Eligible Conditions
- Depression
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ assessed during pet scans before and after rtms therapy (90 minutes per scan)
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~assessed during pet scans before and after rtms therapy (90 minutes per scan)
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Change in Synaptic Density Quantified by Regional Binding Potential (BP_ND)
Trial Design
1Treatment groups
Experimental Treatment
Group I: Major Depression Disorder ParticipantsExperimental Treatment2 Interventions
Participants will undergo positron emission tomography-magnetic resonance (PET-MR) imaging using the \[11C\]UCB-J radiotracer before and after Repetitive Transcranial Magnetic Stimulation (rTMS) treatment
Find a Location
Who is running the clinical trial?
Davidzon, Guido, M.D.Lead Sponsor
2 Previous Clinical Trials
61 Total Patients Enrolled
Stanford UniversityOTHER
2,448 Previous Clinical Trials
17,492,384 Total Patients Enrolled
109 Trials studying Depression
93,866 Patients Enrolled for Depression
Jong H Yoon, MDPrincipal InvestigatorStanford University
1 Previous Clinical Trials
60 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Major Depression Disorder Participants
Awards:
This trial has 3 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Approved for 5 Other Conditions - This treatment demonstrated efficacy for 5 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Depression Patient Testimony for trial: Trial Name: NCT04311619 — Phase 1
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger